References
Product Reference: |●Characterization of new oral antidiabetic agent CS-045. Studies in KK and ob/ob mice and Zucker fatty rats: T. Fujiwara, et al.; Diabetes 37, 1549 (1988)|●An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma): J.M. Lehmann, et al.; J. Biol. Chem. 270, 12953 (1995)|●Growth inhibition of myeloid leukemia cells by troglitazone, a ligand for peroxisome proliferator activated receptor gamma, and retinoids: H. Asou, et al.; Int. J. Oncol. 15, 1027 (1999)|●Ligand type-specific interactions of peroxisome proliferator-activated receptor gamma with transcriptional coactivators: Y. Kodera, et al.; J. Biol. Chem. 275, 33201 (2000)|●Inhibition of human lung cancer cell growth by the peroxisome proliferator-activated receptor-gamma agonists through induction of apoptosis: Y. Tsubouchi, et al.; BBRC 270, 400 (2000)|●Troglitazone and related compounds: therapeutic potential beyond diabetes: T. Fujiwara & H. Horikoshi; Life Sci. 67, 2405 (2000)|●Troglitazone induces apoptosis via the p53 and Gadd45 pathway in vascular smooth muscle cells: T. Okura, et al.; Eur. J. Pharmacol. 407, 227 (2000)|●Troglitazone and related compounds: therapeutic potential beyond diabetes: T. Fujiwara & H. Horikoshi; Life Sci. 67, 2405 (2000) (Review)|●Suppression of nuclear factor-kappaB and stimulation of inhibitor kappaB by troglitazone: evidence for an anti-inflammatory effect and a potential antiatherosclerotic effect in the obese: H. Ghanim, et al.; J. Clin. Endocrinol. Metab. 86, 1306 (2001)|●Nuclear factor-kappaB suppressive and inhibitor-kappaB stimulatory effects of troglitazone in obese patients with type 2 diabetes: A. Aljada, et al.; evidence of an antiinflammatory action?: J. Clin. Endocrinol. Metab. 86, 3250 (2001)|●Peroxisome proliferator-activated receptor-gamma ligands inhibit nuclear but not cytosolic extracellular signal-regulated kinase/mitogen-activated protein kinase-regulated steps in vascular smooth muscle cell migration: S. Goetze, et al.; J. Cardiovasc. Pharmacol. 38, 909 (2001)|●Peroxisome proliferator-activated receptor gamma ligands suppress the transcriptional activation of cyclooxygenase-2. Evidence for involvement of activator protein-1 and CREB-binding protein/p300: K. Subbaramaiah, et al.; J. Biol. Chem. 276, 12440 (2001)|●USBio References
No references available
TDS
NCBI
UniProt
Tech Support
Customer Service
